NASDAQ:TXG

10x Genomics (TXG) Stock Forecast, Price & News

$41.21

-0.14 (-0.34%)

(As of 09/25/2023 ET)

Compare

Today's Range: $40.81
▼
$41.93
50-Day Range: $41.21
▼
$62.98
52-Week Range: $23.81
▼
$63.57

Volume: 1.04 million shs
Average Volume: 966,447 shs
Market Capitalization: $4.84 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $58.73

10x Genomics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 42.5% Upside
$58.73 Price Target
Short Interest: Healthy
4.07% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.73
Upright™ Environmental Score
News Sentiment: 0.11
Based on 5 Articles This Week
Insider Trading: Selling Shares
$4.68 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.76) to ($1.32) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

152nd out of 962 stocks

Analytical Instruments Industry

9th out of 27 stocks

3.3

Analyst's Opinion

Consensus Rating
10x Genomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 7 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $58.73, 10x Genomics has a forecasted upside of 42.5% from its current price of $41.21.
Amount of Analyst Coverage
10x Genomics has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.07% of the outstanding shares of 10x Genomics have been sold short.
Short Interest Ratio / Days to Cover
10x Genomics has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in 10x Genomics has recently decreased by 1.04%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
10x Genomics does not currently pay a dividend.
Dividend Growth
10x Genomics does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
10x Genomics has received a 76.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biochemical assay kits", "Microfluidic biochips", and "Workflow automation software for clinical laboratories" products. See details.
Environmental Sustainability
The Environmental Impact score for 10x Genomics is -0.73.

2.8

News and Social Media Coverage

News Sentiment
10x Genomics has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for 10x Genomics this week, compared to 3 articles on an average week.
Search Interest
8 people have searched for TXG on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.
MarketBeat Follows
10 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,679,516.00 in company stock.
Percentage Held by Insiders
10.65% of the stock of 10x Genomics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
79.16% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for 10x Genomics are expected to grow in the coming year, from ($1.76) to ($1.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of 10x Genomics is -27.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of 10x Genomics is -27.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
10x Genomics has a P/B Ratio of 5.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About 10x Genomics (NASDAQ:TXG) Stock

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

TXG Price History

30 days | 90 days | 365 days | Advanced Chart

TXG Stock News Headlines

September 20, 2023 | americanbankingnews.com

10x Genomics (NASDAQ:TXG) Receives "Buy" Rating from Canaccord Genuity Group

September 19, 2023 | msn.com

Canaccord Genuity Reiterates 10x Genomics Inc - (TXG) Buy Recommendation

September 25, 2023 | Legacy Research (Ad)

Watch SHOCKING Footage of AI Facility with Ties to Elon Musk

I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.

September 19, 2023 | msn.com

NanoString falls afterprelim injunction in Germany in dispute with 10x Genomics (update)

September 18, 2023 | finance.yahoo.com

Unveiling 10x Genomics (TXG)'s Value: Is It Really Priced Right? A Comprehensive Guide

September 14, 2023 | reuters.com

10x Genomics defeats startup's attempt to end gene-analysis patent case

September 14, 2023 | finance.yahoo.com

10x Genomics Expands Gene Expression Flex Offering with New High-Throughput Multiomic Profiling Kit

September 12, 2023 | benzinga.com

Psomagen Puts Spatial Biology and Multiomics in Focus, first CRO to launch 10X Genomics Xenium™ in situ Analyzer services in North America

September 25, 2023 | Legacy Research (Ad)

Watch SHOCKING Footage of AI Facility with Ties to Elon Musk

September 8, 2023 | finance.yahoo.com

10x Genomics (TXG)'s True Worth: A Comprehensive Analysis of Its Market Value

September 8, 2023 | msn.com

10x Genomics: Recent Performance Amplifies My Bullish Conviction

September 5, 2023 | finance.yahoo.com

Study Enabled by 10x Genomics Single Cell and Spatial Technologies Explains Why Immunotherapy is More Effective for Certain Brain Tumors Than Others

August 31, 2023 | msn.com

10x Genomics Inc - (TXG) Price Target Increased by 7.02% to 64.01

August 30, 2023 | finance.yahoo.com

10x Genomics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

August 29, 2023 | finance.yahoo.com

10x Genomics Surpasses 100 Xenium Analyzer Shipments

August 9, 2023 | finance.yahoo.com

We're Not Very Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Rate

August 7, 2023 | msn.com

Morgan Stanley Reiterates 10x Genomics Inc - (TXG) Overweight Recommendation

August 5, 2023 | finanznachrichten.de

10x Genomics, Inc.: 10x Genomics Reports Second Quarter 2023 Financial Results

August 4, 2023 | markets.businessinsider.com

Bank of America Securities Keeps Their Sell Rating on 10x Genomics (TXG)

August 4, 2023 | finance.yahoo.com

Highflier 10x Genomics Sacrifices Breakout As Macro Headwinds Squeeze China

August 4, 2023 | markets.businessinsider.com

Barclays Keeps Their Buy Rating on 10x Genomics (TXG)

August 4, 2023 | finance.yahoo.com

10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say

August 3, 2023 | finance.yahoo.com

10x Genomics Reports Second Quarter 2023 Financial Results

August 3, 2023 | finance.yahoo.com

Buy-Zone-Adjacent 10x Genomics Tops Sales Views, But There's A Caveat

July 13, 2023 | msn.com

Goldman Sachs Maintains 10x Genomics Inc - (TXG) Sell Recommendation

July 13, 2023 | finance.yahoo.com

10x Genomics to Report Second Quarter 2023 Financial Results on August 3, 2023

July 13, 2023 | markets.businessinsider.com

Where 10x Genomics Stands With Analysts

See More Headlines

Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

TXG Company Calendar

Last Earnings: 8/03/2023
Today: 9/25/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Analytical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TXG
CUSIP: N/A
CIK: 1770787
Web: www.10xgenomics.com
Phone: 925-401-7300
Fax: N/A
Employees: 1,243
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $58.73
High Stock Price Forecast: $75.00
Low Stock Price Forecast: $25.00
Forecasted Upside/Downside: +42.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.49)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-166,000,000.00
Net Margins: -30.31%
Pretax Margin: -29.36%
Return on Equity: -21.69%
Return on Assets: -17.11%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.94
Quick Ratio: 5.09

Sales & Book Value

Annual Sales: $516.41 million
Price / Sales: 9.39
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.99 per share
Price / Book: 5.91

Miscellaneous

Outstanding Shares: 117,420,000
Free Float: 104,913,000
Market Cap: $4.85 billion
Optionable: Optionable
Beta: 1.77

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Serge Saxonov Ph.D. (Age 46)
Co-Founder, CEO & Director
Comp: $837.68k

Dr. Benjamin J. Hindson Ph.D. (Age 48)
Co-Founder, Pres, Chief Scientific Officer & Director
Comp: $615.96k

Mr. Justin J. McAnear (Age 47)
Chief Financial Officer
Comp: $535.91k

Mr. Eric S. Whitaker Esq. (Age 56)
Chief Legal Officer
Comp: $558.97k

Mr. James L. Wilbur Ph.D. (Age 58)
Chief Commercial Officer
Comp: $390.78k

Mr. Michael Schnall-Levin
Founding Scientist & CTO

Ms. Cassie Corneau
Mang. of Investor Relations and Strategic Fin.

Ms. Rebecca Port
Chief People Officer

Mr. James Bryant
Director of Legal

Mr. Nikhil Rao
Director of Product Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TXG Stock - Frequently Asked Questions

Should I buy or sell 10x Genomics stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TXG shares.
View TXG analyst ratings or view top-rated stocks.
What is 10x Genomics' stock price forecast for 2023?: 9 brokerages have issued 12-month target prices for 10x Genomics' stock. Their TXG share price forecasts range from $25.00 to $75.00. On average, they predict the company's share price to reach $58.73 in the next year. This suggests a possible upside of 42.2% from the stock's current price.
View analysts price targets for TXG or view top-rated stocks among Wall Street analysts.
How have TXG shares performed in 2023?: 10x Genomics' stock was trading at $36.44 on January 1st, 2023. Since then, TXG shares have increased by 13.3% and is now trading at $41.30.
View the best growth stocks for 2023 here.
When is 10x Genomics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our TXG earnings forecast.
How were 10x Genomics' earnings last quarter?: 10x Genomics, Inc. (NASDAQ:TXG) posted its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by $0.14. The business had revenue of $146.82 million for the quarter, compared to the consensus estimate of $139.97 million. 10x Genomics had a negative trailing twelve-month return on equity of 21.69% and a negative net margin of 30.31%. The company's revenue was up 28.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.57) EPS.
What ETFs hold 10x Genomics' stock?: ETFs with the largest weight of 10x Genomics (NASDAQ:TXG) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ARK Genomic Revolution ETF (ARKG), Fidelity Disruptive Medicine ETF (FMED), ARK Innovation ETF (ARKK), BNY Mellon Innovators ETF (BKIV), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and Principal Healthcare Innovators ETF (BTEC).
What guidance has 10x Genomics issued on next quarter's earnings?: 10x Genomics issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $600.00 million-$620.00 million, compared to the consensus revenue estimate of $600.73 million.
What is Serge Saxonov's approval rating as 10x Genomics' CEO?: 25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did 10x Genomics IPO?: (TXG) raised $297 million in an initial public offering on Thursday, September 12th 2019. The company issued 9,000,000 shares at $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager.
What is 10x Genomics' stock symbol?: 10x Genomics trades on the NASDAQ under the ticker symbol "TXG."
Who are 10x Genomics' major shareholders?: 10x Genomics' stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (7.32%), BlackRock Inc. (4.65%), Sands Capital Management LLC (3.55%), ARK Investment Management LLC (2.68%), Brown Capital Management LLC (2.65%) and SRS Investment Management LLC (1.87%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, James Wilbur, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Mathai Mammen, Serge Saxonov and Sridhar Kosaraju.
View institutional ownership trends.
How do I buy shares of 10x Genomics?: Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is 10x Genomics' stock price today?: One share of TXG stock can currently be purchased for approximately $41.30.
How much money does 10x Genomics make?: 10x Genomics (NASDAQ:TXG) has a market capitalization of $4.85 billion and generates $516.41 million in revenue each year. The company earns $-166,000,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.
How many employees does 10x Genomics have?: The company employs 1,243 workers across the globe.
How can I contact 10x Genomics?: 10x Genomics' mailing address is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. The official website for the company is www.10xgenomics.com. The company can be reached via phone at 925-401-7300 or via email at investors@10xgenomics.com.

This page (NASDAQ:TXG) was last updated on 9/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial